Side-by-side · Research reference
Follistatin-344vsSNAP-8
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AHuman-MechanisticHUMAN-REVIEWED4/58 cited
BHuman-MechanisticHUMAN-REVIEWED8/46 cited
Follistatin-344
Myostatin/Activin Antagonist · Research Use
15–25%FST/MSTN ratio ↑
344 AACirculating isoform
ResearchPhase status
Research · No approved protocol
SNAP-8
Synthetic Octapeptide · Cosmetic Topical
TopicalRoute
8-AAPeptide length
SNAREPrimary target
Topical · Facial application · Twice daily
01Mechanism of Action
Parameter
Follistatin-344
SNAP-8
Primary target
Myostatin (MSTN/GDF-8) and Activin A
SNARE complex (SNAP-25 competitive binding site)
Pathway
FST-344 binds MSTN/Activin → prevents ActRIIB receptor engagement → disinhibits muscle anabolism
Acetyl octapeptide-3 → SNARE complex disruption → Reduced vesicular fusion → Decreased acetylcholine release → Muscle relaxation
Downstream effect
Elevated follistatin/myostatin ratio, increased muscle protein synthesis, attenuated muscle atrophy signalingJeong 2026
Transient reduction in neuromuscular signal transmission, decreased muscle contraction amplitude, wrinkle depth reduction
Feedback intact?
Yes — indirect antagonist, preserves endogenous regulation
N/A — topical cosmetic, no systemic endocrine axis
Origin
Endogenous glycoprotein, 344-AA isoform lacking heparin-binding domain (vs FST-315)
Synthetic peptide derived from N-terminal fragment of SNAP-25 protein (synaptosomal-associated protein 25 kDa)
Antibody development
Not documented in available trials (endogenous protein)
—
02Dosage Protocols
Parameter
Follistatin-344
SNAP-8
Clinical protocol
None — no approved dosing regimen
Follistatin-344 measured as endogenous biomarker, not administered exogenously in cited trials.
—
Research context
Endogenous modulation via exercise + nutrition
Resistance training + EAA intake elevated FST/MSTN ratio by 15–25% in 12-week RCT (older women).
—
Evidence basis
Human observational / biomarker studies
RCT, in vitro skin penetration studies
Half-life
Not established
Circulating isoform; lacks tissue-binding domain of FST-315.
—
Typical concentration
—
2–10% in cosmetic formulationsLupin 2024Raikou 2017
Commercial products typically use 5–10%.
Treatment duration
—
20–60 days for visible effectRaikou 2017
Skin microtopography improvements measured at 20-day intervals.
Formulation type
—
Oil-in-water emulsion, serum, cream
Application site
—
Facial skin — glabellar lines, crow's feet, forehead
03Metabolic / Fat Loss Evidence
Parameter
Follistatin-344
SNAP-8
Primary target
Muscle mass preservation, not direct lipolysis
—
Indirect fat effect
Increased lean mass → elevated resting metabolic rate
Not primary mechanism. Muscle-sparing during deficit.
—
Clinical evidence
Lorcaserin trial (6 mo) showed no MAFI axis changes during fat lossRamirez-Cisneros 2026
Suggests follistatin not primary driver of fat loss in weight-reduction interventions.
—
GLP-1RA studies
Liraglutide (35 days) — no significant MAFI axis modulation despite fat/lean changes
—
04Side Effects & Safety
Parameter
Follistatin-344
SNAP-8
Clinical safety data
None — no human exogenous administration trials in literature
—
Theoretical risks
Excessive myostatin inhibition → muscle overgrowth, impaired glucose tolerance
Based on myostatin-null animal models and clinical myostatin inhibitor trials.
—
Endogenous elevation (exercise)
No adverse effects reported in 12-week resistance + EAA trials
—
Cancer risk (theoretical)
Myostatin inhibition may promote tumor growth in malignancy (preclinical data)
—
Regulatory status
Not approved for human use — research peptide only
—
Cytotoxicity
—
Concentration-dependent antiproliferative effect observed in vitro; IC50 ~10 mg/mL (argireline, 6-AA analogue)
Commercial formulations typically use 0.05–0.1 mg/mL, well below cytotoxic threshold.
Skin irritation
—
Minimal; well-tolerated in clinical use
Peptide oxidation
—
Methionine residue susceptible to oxidation in formulation; may reduce efficacyKluczyk 2021
Formulation stability issue, not a direct adverse effect.
Hypersensitivity
—
Rare; no widespread allergic reactions reported
Absolute Contraindications
Follistatin-344
- ·Active malignancy
- ·No approved protocol — research use only
SNAP-8
- ·Known hypersensitivity to acetyl octapeptide-3 or formulation excipients
Relative Contraindications
Follistatin-344
- ·Insulin resistance / Type 2 diabetes (monitor glucose)
- ·Pregnancy / lactation (unknown safety profile)
SNAP-8
- ·Active skin infections or open wounds at application site
- ·Neuromuscular disorders (theoretical concern, no documented cases)
05Administration Protocol
Parameter
Follistatin-344
SNAP-8
1. Regulatory status
Follistatin-344 is not approved for human administration. All cited studies measure endogenous serum follistatin as a biomarker, not as an exogenous therapeutic agent.
Wash face with gentle cleanser and pat dry. Remove makeup and surface oils to optimize peptide contact.
2. Endogenous modulation
Resistance exercise combined with essential amino acid (EAA) supplementation elevated the follistatin/myostatin ratio by 15–25% in 12-week randomized trials. Protein intake (1.2–1.5 g/kg/day) synergizes with training to upregulate endogenous follistatin.
Apply 1–2 drops or pea-sized amount of SNAP-8 serum or cream to target areas (forehead, glabellar lines, crow's feet). Gently massage until absorbed.
3. Measurement context
Serum follistatin and follistatin/myostatin ratio are used diagnostically in sarcopenia screening and as biomarkers of muscle anabolic balance in clinical trials.
Twice daily — morning and evening. Allow 2–3 minutes for absorption before applying additional skincare products.
4. Research consideration
Gene therapy and recombinant follistatin delivery are under preclinical investigation for muscular dystrophy and sarcopenia. No human safety or efficacy data for exogenous FST-344 administration.
Apply before heavier creams or occlusive moisturizers. Peptides penetrate best from water-based serums on clean skin.
5. Storage
—
Store at room temperature, away from direct sunlight. Refrigeration may extend shelf life of formulations containing unstable peptides.
6. Duration
—
Consistent use for 20–60 days required for visible wrinkle reduction. Effects are temporary and reverse upon discontinuation.
06Stack Synergy
Follistatin-344
+ BPC-157
Multi-pathwayFollistatin-344 (myostatin antagonist) and BPC-157 (tissue repair peptide) address complementary pathways in muscle recovery. FST-344 promotes muscle protein synthesis by disinhibiting myostatin signaling, while BPC-157 accelerates healing of tendons, ligaments, and microtears via angiogenesis and collagen synthesis. Combined, they may support both hypertrophy and structural repair during high-volume training or injury recovery.
- Follistatin-344
- No approved protocol — endogenous modulation via resistance exercise + EAA
- BPC-157
- 250–500 mcg SQ · twice daily · near injury site or systemic
- Duration
- 4–8 weeks
- Primary benefit
- Muscle hypertrophy + accelerated soft tissue repair
+ TB-500
ModerateTB-500 (thymosin beta-4 fragment) promotes cell migration, angiogenesis, and anti-inflammatory signaling in muscle and connective tissue. Follistatin-344's anabolic signaling may synergize with TB-500's regenerative effects during muscle damage or overtraining, particularly in older adults where both myostatin inhibition and tissue repair are rate-limiting.
- Follistatin-344
- Endogenous upregulation (resistance training + protein)
- TB-500
- 2–5 mg SQ · twice weekly · loading phase 4 weeks, then maintenance
- Frequency
- Twice weekly TB-500, daily training stimulus for FST
- Primary benefit
- Enhanced recovery, reduced inflammation, muscle growth support
SNAP-8
— no documented stacks